Annexon Submits Marketing Authorization Application To EMA For Tanruprubart For Treatment Of Guillain-Barré Syndrome
Benzinga Newsdesk 10 months ago
News
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of CareBLA Submission with U.S./European Data from FORWARD Trial Planned in 2026BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) --
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care
BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026
BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart for the treatment of Guillain-Barré syndrome (GBS).